CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer
Clinical trial NCT05585814 · RECRUITING
Trial details
- NCT number
- NCT05585814
- Sponsor
- Shanghai Changzheng Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-01
- Primary completion
- 2024-10-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.